+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Controlled evaluation of the beta adrenoceptor blocking drug oxprenolol in anxiety



Controlled evaluation of the beta adrenoceptor blocking drug oxprenolol in anxiety



Medical Journal of Australia 1(24): 909-912



An investigation of the effectiveness of the beta adrenoceptor blocking drug oxprenolol in the treatment of primary clinical anxiety is reported. A controlled double-blind evaluation of oxprenolol versus diazepam and placebo was carried out. The results of the trial showed diazepam to be generally more effective and to produce a more rapid onset of symptom reduction than oxprenolol. The role of beta adrenergic blocking drugs in the treatment of clinical anxiety and related syndromes is discussed.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039683725

Download citation: RISBibTeXText

PMID: 790112


Related references

Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation. British Journal of Clinical Pharmacology 12(6): 869-871, 1981

The assessment in man of the beta-adrenoceptor blocking activity and cardioselectivity of H-I 42 BS, a long acting beta-adrenoceptor blocking drug. British Journal of Clinical Pharmacology 23(4): 411-423, 1987

Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. Naunyn-Schmiedeberg's Archives of Pharmacology 316(1): 19-23, 1981

A structured approach to the development of a controlled release drug delivery system for a beta adrenoceptor blocking drug. Anderson, J M , S W Kim And K Knutson (Ed ) Advances in Drug Delivery Systems, Vol 4; International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, Usa, February 21-24, 1989 X+359p Elsevier Science Publishers B V : Amsterdam, Netherlands; New York, New York, Usa Illus 307-314, 1990

Adrenoceptor blocking hemodynamic and coronary effects of YM-09538, a new combined alpha- and beta-adrenoceptor blocking drug, in anesthetized dogs. European Journal of Pharmacology 85(1): 35-50, 1982

Comparison of beta-adrenoceptor blocking properties of sotalol, oxprenolol, propranolol and pindolol on rabbit intestinal smooth muscle. Pharmacology 13(5): 441-447, 1975

An assessment of beta-adrenoceptor blockade in man by SK & F 92657, a new drug with combined vasodilator and beta-adrenoceptor blocking actions, and comparison with propranolol. British Journal of Clinical Pharmacology 9(3): 300p-301p, 1980

Combined alpha and beta adrenoceptor blocking drug ah 5158 5 1 hydroxy 2 1 methyl 3 phenylpropyl amino ethyl salicylamide further studies on specificity and alpha adrenoceptor blocking action. Proceedings of the Australian Physiological & Pharmacological Society 5(2): 216-217, 1974

Metabolism of a beta blocking drug, oxprenolol. Journal of Pharmacology and Experimental Therapeutics 179(2): 354-358, 1971

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drug. American Heart Journal 99(1): 124-128, 1980

Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug. Clinical Pharmacology and Therapeutics 24(2): 168-174, 1978

Evaluation of the beta-adrenoceptor blocking activity of the Class Ic antiarrhythmic drug diprafenone in man. European Journal of Clinical Pharmacology 36(6): 579-582, 1989

Oxprenolol: clinical experiences with a new beta-adrenergic blocking drug. Medical Journal of Australia 1(4): 170-173, 1970

Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency. Schweizerische Medizinische Wochenschrift 111(49): 1915-1918, 1981

Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers. British Journal of Clinical Pharmacology 19 Suppl 2: 197s-201s, 1985